Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Author(s):: Boer, S.M. de (0000-0002-8454-1597); Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Kruitwagen, R.F.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.; Putter, H.; Creutzberg, C.L. (0000-0002-7008-4321); PORTEC Study Grp

Published: 2016
Publication type: Article / Letter to editor

Date issued: 2016
Language: English
Is part of: The Lancet. Oncology
hdl: 1887/3280399
doi: 10.1016/S1470-2045(16)30120-6
URL: http://europepmc.org/abstract/med/27397040